The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization

Howard, 2003, Dynamics and mechanics of the microtubule plus end, Nature, 422, 753, 10.1038/nature01600 Desai, 1997, Microtubule polymerization dynamics, Annu Rev Cell Dev Biol, 13, 83, 10.1146/annurev.cellbio.13.1.83 Downing, 2000, Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics, Annu Rev Cell Dev Biol, 16, 89, 10.1146/annurev.cellbio.16.1.89 Jordan, 2004, Microtubules as a target for anticancer drugs, Nat Rev Cancer, 4, 253, 10.1038/nrc1317 Nogales, 1998, Structure of the alpha beta tubulin dimer by electron crystallography, Nature, 391, 199, 10.1038/34465 Prota, 2013, Molecular mechanism of action of microtubule-stabilizing anticancer agents, Science, 339, 587, 10.1126/science.1230582 Prota, 2014, Structural basis of microtubule stabilization by laulimalide and peloruside A, Angew Chem Int Ed Engl, 53, 1621, 10.1002/anie.201307749 Gigant, 2005, Structural basis for the regulation of tubulin by vinblastine, Nature, 435, 519, 10.1038/nature03566 Ravelli, 2004, Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain, Nature, 428, 198, 10.1038/nature02393 Duran, 2010, In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(−) human breast and ovarian cancer variants selected for resistance to taxanes, Proc Am Assoc Cancer Res, 51, 1070 Estève, 2010, BAL27862: a unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance, Proc Am Assoc Cancer Res, 51, 480 Calvert, 2013, A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors, J Clin Oncol, 31, 2566, 10.1200/jco.2013.31.15_suppl.2566 Bachmann, 2009, BAL27862: a novel anticancer agent that dissociates microtubules and creates a distinct cellular phenotype, Mol Cancer Ther, 8, C229, 10.1158/1535-7163.TARG-09-C229 Wong, 2005, Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo, Clin Cancer Res, 11, 6002, 10.1158/1078-0432.CCR-05-0209 Na, 1985, Velocity sedimentation study of ligand-induced protein self-association, Methods Enzymol, 117, 459, 10.1016/S0076-6879(85)17026-6 Himes, 1991, Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules, Pharmacol Ther, 51, 257, 10.1016/0163-7258(91)90081-V Owellen, 1972, The binding of vincristine, vinblastine and colchicine to tubulin, Biochem Biophys Res Commun, 47, 685, 10.1016/0006-291X(72)90546-3 Lambeir, 1981, A fluorescence stopped flow study of colchicine binding to tubulin, J Biol Chem, 256, 3279, 10.1016/S0021-9258(19)69603-1 Fernando, 1991, Kinetics of dissociation of the tubulin-colchicine complex. Complete reaction scheme and comparison to thermodynamic measurements., J Biol Chem, 266, 2890, 10.1016/S0021-9258(18)49931-0 Cornish-Bowden, 1974, Statistical considerations in the estimation of enzyme kinetic parameters by the direct linear plot and other methods, Biochem J, 139, 721, 10.1042/bj1390721 Cruz-Monserrate, 2003, Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel–Dreyer chromatography, Eur J Biochem, 270, 3822, 10.1046/j.1432-1033.2003.03776.x Singer, 1988, Effect of solution variables on the binding of vinblastine to tubulin, Biochem Pharmacol, 37, 2691, 10.1016/0006-2952(88)90264-X Williams, 1983, High-performance liquid chromatographic application of the Hummel and Dreyer method for the determination of colchicine-tubulin binding parameters, J Chromatogr, 266, 141, 10.1016/S0021-9673(01)90886-6 Bhattacharyya, 1974, Promotion of fluorescence upon binding of colchicine to tubulin, Proc Natl Acad Sci U S A, 71, 2627, 10.1073/pnas.71.7.2627 Prota, 2013, Structural basis of tubulin tyrosination by tubulin tyrosine ligase, J Cell Biol, 200, 259, 10.1083/jcb.201211017 Karplus, 2012, Linking crystallographic model and data quality, Science, 336, 1030, 10.1126/science.1218231 Davis, 2004, MolProbity: structure validation and all-atom contact analysis for nucleic acids and their complexes, Nucleic Acids Res, 32, W615, 10.1093/nar/gkh398 Dorleans, 2009, Variations in the colchicine-binding domain provide insight into the structural switch of tubulin, Proc Natl Acad Sci U S A, 106, 13775, 10.1073/pnas.0904223106 Lowe, 2001, Refined structure of alpha beta-tubulin at 3.5Å resolution, J Mol Biol, 313, 1045, 10.1006/jmbi.2001.5077 Ayaz, 2012, A TOG:alphabeta-tubulin complex structure reveals conformation-based mechanisms for a microtubule polymerase, Science, 337, 857, 10.1126/science.1221698 Pecqueur, 2012, A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end, Proc Natl Acad Sci U S A, 109, 12011, 10.1073/pnas.1204129109 Fontana, 2004, Probing protein structure by limited proteolysis, Acta Biochim Pol, 51, 299, 10.18388/abp.2004_3573 Sackett, 1993, Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin, Biochemistry, 32, 13560, 10.1021/bi00212a023 Sackett, 1995, Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents, Biochemistry, 34, 7010, 10.1021/bi00021a012 Rovini, 2012, Antitumor activity of BAL27862 (active moiety of the prodrug BAL101553) is associated with the generation of short non-centrosomal microtubules, Eur J Cancer, 148, 128, 10.1016/S0959-8049(12)72220-7 van,, 2001, Role of formulation vehicles in taxane pharmacology, Invest New Drugs, 19, 125, 10.1023/A:1010618632738 Andreu, 2007, Large scale purification of brain tubulin with the modified Weisenberg procedure, Methods Mol Med, 137, 17, 10.1007/978-1-59745-442-1_2 Bai, 1990, Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites, J Biol Chem, 265, 17141, 10.1016/S0021-9258(17)44880-0 Panda, 2000, Interaction of the antitumor compound cryptophycin-52 with tubulin, Biochemistry, 39, 14121, 10.1021/bi0010827 Dorleans, 2007, Studying drug-tubulin interactions by X-ray crystallography, Methods Mol Med, 137, 235, 10.1007/978-1-59745-442-1_16 Kabsch, 2010, XDS, Acta Crystallogr Sect D Biol Crystallogr, 66, 125, 10.1107/S0907444909047337 Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr Sect D Biol Crystallogr, 66, 213, 10.1107/S0907444909052925 Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr Sect D Biol Crystallogr, 60, 2126, 10.1107/S0907444904019158